Insider Trading June 8, 2026 05:31 PM

Casdin Capital and Director Eli Casdin Acquire $11.1M in GeneDx Shares Amid Stock Decline

Funds affiliated with Casdin Capital and GeneDx director Eli Casdin purchased 200,000 shares last week, signaling potential confidence as the stock trades 67% below its six-month high.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
WGS

Funds affiliated with Casdin Capital and GeneDx director Eli Casdin have acquired approximately $11.1 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) shares across two transactions last week. The purchases, totaling 200,000 shares of Class A Common Stock, took place on June 4 and June 5, with prices ranging from $52.8566 to $56.4449 per share. The transactions were primarily executed by Casdin Partners Master Fund, L.P., with Casdin Capital, LLC serving as the investment adviser and Casdin Partners GP, LLC as the general partner. Eli Casdin, the managing member of both entities, is also a director and a ten percent owner of GeneDx Holdings Corp. The insider purchases come as GeneDx shares have declined 67% over the past six months, with the stock currently trading at $51.75. According to InvestingPro analysis, which tracks 10+ additional tips for WGS, analysts predict the company will be profitable this year despite recent volatility. The $1.55 billion market cap company maintains a

Casdin Capital and Director Eli Casdin Acquire $11.1M in GeneDx Shares Amid Stock Decline
WGS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Casdin Capital and director Eli Casdin acquired $11.1M in GeneDx shares, signaling potential confidence.
  • GeneDx shares have declined 67% over the past six months, currently trading at $51.75.
  • Analysts predict GeneDx will be profitable this year despite recent volatility.

Funds affiliated with Casdin Capital and director Eli Casdin acquired approximately $11.1 million worth of shares in GeneDx Holdings Corp. (NASDAQ:WGS) across two transactions last week. The purchases, totaling 200,000 shares of Class A Common Stock, took place on June 4 and June 5, with prices ranging from $52.8566 to $56.4449 per share.

The transactions were primarily made by Casdin Partners Master Fund, L.P. The filing indicates that Casdin Capital, LLC, which serves as the investment adviser to the Master Fund, along with Casdin Partners GP, LLC, the general partner of the Master Fund, and Eli Casdin, who is the managing member of both Casdin Capital and the GP, may be deemed indirect beneficial owners of these securities. Eli Casdin is also a director and a ten percent owner of GeneDx Holdings Corp.

The insider purchases come as GeneDx shares have declined 67% over the past six months, with the stock currently trading at $51.75. According to InvestingPro analysis, which tracks 10+ additional tips for WGS, analysts predict the company will be profitable this year despite recent volatility. The $1.55 billion market cap company maintains a

Risks

  • GeneDx reported a first-quarter 2026 earnings miss, with EPS of -$0.28 compared to the forecasted -$0.01.
  • Revenue fell short of expectations, coming in at $102.3 million compared to the expected $112.45 million.
  • Canaccord and BTIG both adjusted their price targets for GeneDx, reflecting a softer revenue outlook.

More from Insider Trading

First Citizens Bancshares CEO Frank Holding Jr. Acquires $394k in Shares Amid Management Buyback Activity Jun 8, 2026 First Citizens Bancshares CEO Frank Holding Jr. Executes $643,467 Class B Share Acquisition Jun 8, 2026 First Citizens Bancshares Chief Executive Acquires $1 Million Stake in Class B Shares Jun 8, 2026 Intuitive Machines Insider Transaction and Market Context Jun 8, 2026 Roblox Legal Officer Executes Pre-Arranged Share Sale Amid Valuation Debate Jun 8, 2026